INmune Bio Inc. will host a conference call on August 7, 2025, to discuss Q2 results and corporate updates.
Quiver AI Summary
INmune Bio Inc. announced that it will host a conference call and webcast on August 7, 2025, at 4:30 PM ET to discuss its financial results for the quarter ending June 30, 2025, and provide a corporate update. Interested participants can join the call by dialing in about 5 to 10 minutes beforehand, and a live audio webcast will also be available. The company is focused on developing treatments that engage the innate immune system, with product platforms addressing diseases such as Alzheimer’s and cancer. INmune Bio emphasizes that its clinical trials are in early stages and that there are risks and uncertainties associated with the development and commercialization of its product candidates. Contact information for the company's CFO and Head of Investor Relations is also provided.
Potential Positives
- INmune Bio will host a conference call on August 7, 2025, to discuss its quarterly results and provide a corporate update, indicating transparency and engagement with investors.
- The company is in clinical development of multiple innovative therapies targeting serious diseases, including Alzheimer’s and cancer, highlighting its active role in advancing medical science.
- INmune Bio has a diverse pipeline with three distinct product platforms, showcasing its commitment to tackling various health issues driven by chronic inflammation and cancer.
Potential Negatives
- The company has not received FDA approval for its product candidates, which may indicate regulatory challenges ahead.
- The press release emphasizes the early stages of clinical trials and the uncertainty in achieving specific outcomes, potentially raising concerns among investors about the company's viability.
- The reliance on substantial additional funding poses a risk to the company's operations and could affect its ability to continue research and development efforts.
FAQ
When is the INmune Bio conference call?
The INmune Bio conference call is scheduled for August 7th, 2025, at 4:30 PM Eastern Time.
How can I participate in the conference call?
You can participate by dialing 1-800-225-9448 or +1-203-518-9783 for international callers about 5-10 minutes before the call.
Will there be a transcript of the conference call?
Yes, a transcript will be available approximately 24 hours after the scheduled call.
How can I access the live audio webcast?
The live audio webcast can be accessed via the provided link: https://viavid.webcasts.com/starthere.jsp?ei=1719932&tp_key=2300519883.
What is INmune Bio's focus as a company?
INmune Bio is focused on developing treatments that target the innate immune system to fight diseases like Alzheimer's and cancer.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INMB Hedge Fund Activity
We have seen 40 institutional investors add shares of $INMB stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RENAISSANCE TECHNOLOGIES LLC removed 185,800 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,451,098
- RAYMOND JAMES FINANCIAL INC removed 93,510 shares (-19.7%) from their portfolio in Q1 2025, for an estimated $730,313
- VANGUARD GROUP INC added 88,412 shares (+12.0%) to their portfolio in Q1 2025, for an estimated $690,497
- DEUTSCHE BANK AG\ removed 71,837 shares (-65.4%) from their portfolio in Q1 2025, for an estimated $561,046
- MORGAN STANLEY removed 70,662 shares (-45.6%) from their portfolio in Q1 2025, for an estimated $551,870
- DAUNTLESS INVESTMENT GROUP, LLC removed 61,142 shares (-31.9%) from their portfolio in Q1 2025, for an estimated $477,519
- WARATAH CAPITAL ADVISORS LTD. added 53,774 shares (+inf%) to their portfolio in Q1 2025, for an estimated $419,974
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$INMB Analyst Ratings
Wall Street analysts have issued reports on $INMB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 07/02/2025
- Scotiabank issued a "Sector Underperform" rating on 07/01/2025
To track analyst ratings and price targets for $INMB, check out Quiver Quantitative's $INMB forecast page.
$INMB Price Targets
Multiple analysts have issued price targets for $INMB recently. We have seen 2 analysts offer price targets for $INMB in the last 6 months, with a median target of $4.3.
Here are some recent targets:
- Jason McCarthy from Maxim Group set a target price of $8.0 on 07/02/2025
- George Farmer from Scotiabank set a target price of $0.6 on 07/01/2025
Full Release
Management to host conference call and webcast at 4:30 pm ET on that day
Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, August 7 th , 2025 at 4:30pm EDT to discuss results for its quarter ended June 30, 2025 and to provide a corporate update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator.
Date: August 7 th , 2025
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-225-9448 Participant Dial-in (international): +1-203-518-9783
Conference ID: INMUNE
A live audio webcast of the call can be accessed by clicking here or using this link:
https://viavid.webcasts.com/starthere.jsp?ei=1719932&tp_key=2300519883
A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through August 21, 2025 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering pin no. 11159128.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical development to determine if they can treat Alzheimer’s disease and other indications (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom™, is a proprietary allogeneic, pooled, human umbilical cord-derived mesenchymal Stromal cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio’s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro™, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™, pegipanermin ), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
Company Contact:
David Moss
Chief Financial Officer
(561) 710-0512
[email protected]
Daniel Carlson
Head of Investor Relations
(415) 509-4590
[email protected]
